Navigation Links
Macrocyclics presenta nuevos productos
Date:1/10/2014

DALLAS, 10 de enero de 2014 /PRNewswire/ -- Macrocyclics, Inc. (compañía de AREVA Med) anunció hoy la presentación de cuatro nuevos productos que ampliarán las aplicaciones de imágenes PET con cobre-64 y galio-68 usando plataformas quelatantes basadas en NOTA. Además, un nuevo conjugado de DOTA basado en serotonina ofrece el potencial para obtener imágenes de neurotransmisión serotoninérgicas utilizando un radioisótopo o con gadolinio mediante imágenes por resonancia magnética (MRI).

(Logo: http://photos.prnewswire.com/prnh/20130523/DA20136LOGO)

Visite www.macrocyclics.com para obtener más información.

MÁS ACERCA DE MACROCYCLICS
Macrocyclics es el líder global en tecnologías de agentes quelatantes de alto desempeño para la medicina desde 1995. El equipo de Macrocyclics se dedica a proveer a los clientes agentes quelatantes y servicios tanto establecidos como innovadores para superar los desafíos de las imágenes moleculares y la medicina nuclear. www.macrocyclics.com

MÁS ACERCA DE AREVA MED
AREVA Med es una subsidiaria de AREVA que se especializa en el desarrollo de tratamientos innovadores para luchar contra el cáncer. AREVA Med creó nuevos procesos para producir plomo-212 (²¹²Pb) de alta pureza, un metal poco común que actualmente se encuentra en el centro de prometedoras investigaciones de medicina nuclear. En 2011, AREVA Med adquirió Macrocyclics, líder global en tecnología de agentes quelatantes de alto desempeño. AREVA Med también formó alianzas con socios científicos de primer nivel, como el Instituto Nacional del Cáncer (National Cancer Institute, NCI), la Universidad de Alabama en Birmingham (University of Alabama at Birmingham, UAB) y el Instituto Nacional Francés de Salud e Investigación Médica (French National Institute of Health and Medical Research, Inserm). En 2012, AREVA Med y Roche formaron una alianza estratégica para crear nuevos tratamientos avanzados de radioinmunoterapia alfa para atacar y matar ciertos tipos de células cancerígenas muy agresivas. Para obtener más información: http://arevamed.areva.com/ o www.targetedtrials.com.

Macrocyclics
Garry Kiefer
Teléfono: +1 972 250 2248
Fax: +1 972 250 2245
info@macrocyclics.com

AREVA Med
Alison Tise
Teléfono: +1 301 841 1673
Fax: +1 434 382 4250
alison.tise@areva.com

FUENTE  Macrocyclics, Inc.

FUENTE Macrocyclics, Inc.


'/>"/>
SOURCE Macrocyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Macrocyclics apresenta novos produtos
2. Macrocyclics introduces new products
3. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
4. Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan
5. Cepheid to Webcast Upcoming Financial Presentation
6. Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and Upcoming Presentation Schedules - Research Report Quest Diagnostics, Avanir, Sirona, Ligand and Genomic Health
7. Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
8. Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting
9. Ambit Announces Presentations At The 55th Annual Meeting Of The American Society Of Hematology (ASH)
10. Highland Instruments, Inc., Announces Presentation of "Effects of Electrosonic Stimulation on the Perception of Chronic Pain Due to Osteoarthritis of the Knee."
11. Nora Therapeutics Announces New Time for Presentation at the Oppenheimer 24th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 29, 2017 Center Point Clinical ... platform, announced today study results presented in two ... #AMCP2017, Managed Care and Specialty Pharmacy annual meeting ... in both posters demonstrated that pharmacist-led patient interventions during ... These factors are crucial to generating the robust and ...
(Date:3/28/2017)... This morning,s research on ... The Medicines Co. (NASDAQ: MDCO), Ironwood Pharmaceuticals Inc. ... Supernus Pharmaceuticals Inc. (NASDAQ: SUPN ). ... which is governed by the same governing framework ... industry are wholesalers, retailers, pharmacies, and benefit managers. Learn ...
(Date:3/28/2017)... ROCKVILLE, Md. , March 28, 2017 /PRNewswire/ ... dedicated to innovative therapeutics addressing cancer and other ... at the American Association for Cancer Research annual ... April 3 is entitled "Evaluation of ENMD-2076 ... and the second poster to be presented ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 28, 2017 , ... Resoundant, Inc., the developer of ... Healthineers annual customer education symposium, a world-class learning conference that offers educational content ... - 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , Innovations ...
(Date:3/28/2017)... NY (PRWEB) , ... March 28, 2017 , ... ... process management software and services, is proud to announce it has joined the ... professional association representing the interests of chronically ill, disabled, and dying Americans of ...
(Date:3/28/2017)... , ... March 28, 2017 , ... WHO: , Dr. ... Bark , WHAT: , Medical doctors and PhD scientists will speak to the press ... President Trump in support of an independent vaccine safety commission. , WHERE: , ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... relocated its corporate headquarters to a new, more expansive office space in order ... 2016, Qualidigm purchased a distressed office building in Wethersfield, Conn. located at 936 ...
(Date:3/28/2017)... Florida (PRWEB) , ... March 28, 2017 , ... The ... Corp to raise money to for the Toys for Tots Literacy Campaign at their ... budget in excess of $70 billion, the U.S. ranks at number 14 internationally in ...
Breaking Medicine News(10 mins):